BioSpace News Archive

Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat) .

SeaStar Medical and LMF Acquisition Opportunities, Inc. announced the publication of results from SeaStar Medical’s pilot SCD 005 clinical study to evaluate the safety and clinical outcomes of extracorporeal immunomodulation treatment with SeaStar Medical’s Selective Cytopheretic Device in COVID-19 patients with multiple organ failure in the intensive care unit.

Facilities and processes key to protecting workers and the environment, the paper in Drug Development & Delivery says.

Often undetected until it has progressed to an advanced stage, pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer.

PEI supports BiondVax’s plan for first-in-human clinical trial to be conducted in patients as a combined Phase 1/2a, testing both safety and efficacy, thereby shortening BiondVax’s clinical development timelines for its first NanoAb product, a COVID-19 therapeutic.

CohBar, Inc. announced that its Chief Executive Officer, Dr. Joseph Sarret, will participate at two upcoming conferences.

Prolacta Bioscience®, the world’s leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that top-ranked analyst David Steinberg has been appointed as chief financial officer.

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases announces that Dr. Hubert Chen, MD has joined the company as Chief Scientific Officer and President.

According to the latest report by Reports and Data, the global carotenoids market size was USD 1.89 billion in 2020 and is expected to reach USD 2.19 billion in 2028 and register a revenue CAGR of 3.5% during the forecast period, 2021-2028.

MMS Holdings, a data-focused Contract Research Organization (CRO), is pleased to announce a strategic partnership with Medidata, a Dassault Systèmes company, to provide clients a full range of solutions for clinical data management (CDM) and decentralized clinical trial (DCT) technologies, including Medidata’s unified platform and Rave EDC (Electronic Data Capture).